Adversarial Injection · Sevoflurane (CAS 28523-86-6) OSHA No PEL / ACGIH No TLV / NIOSH REL 2 ppm Ceiling Halogenated Anesthetic / Waste Anesthetic Gas / Operating Room Dental Veterinary · Attack #415

Sevoflurane (Fluoromethyl 2,2,2-Trifluoro-1-(Trifluoromethyl)Ethyl Ether; CAS 28523-86-6; MW 200.05 g/mol; Boiling Point 58.5°C; Vapor Pressure 157 mmHg at 20°C; MAC [Minimum Alveolar Concentration] 2.0% [20,000 ppm]; Blood:Gas Partition Coefficient 0.65 [Low — Rapid Induction/Recovery]; Sweet Ethereal Odor; OSHA: No Specific PEL for Sevoflurane [29 CFR 1910.1000 Z-1/Z-2 Does Not List Sevoflurane; OSHA covers WAG under 1910.1000 Engineering Controls Guidance Only]; ACGIH: No Current TLV [ACGIH Withdrew General "Halogenated Anesthetic Agents" TLV in 2001 Annual Revision — "Insufficient Data to Establish a TLV-TWA"; Not Equivalent to "Never Evaluated"]; NIOSH: REL 2 ppm Ceiling [8-hr; Halogenated Anesthetic Agents; NIOSH 2007 Criteria Document — Applies as Ceiling, Not TWA]; Metabolism: CYP2E1 → Compound A [Fluoromethyl-2,2-Difluoro-1-[Trifluoromethyl]Vinyl Ether; PMVK; Nephrotoxin in Rats at Concentrations >50 ppm-hr]; Fluoride Ion [Inorganic F⁻; >50 µmol/L Serum Fluoride → Nephrotoxicity Risk]; IARC: Not Classified; Reproductive Effects: Animal Data — Embryotoxic at High Anesthetic Doses; Occupational Cohort Data: Spontaneous Abortion Rate Elevation in OR Staff Without Scavenging; Current Most-Used Inhalation Anesthetic in US — Replaced Isoflurane in Most Hospital and Ambulatory Settings Post-2000) — Surgical Suite CRNA Gas Station (Mayo Clinic Rochester MN), Dental Inhalation Sedation (Heartland Dental Overland Park KS), and Veterinary Gas Induction (Veterinary Emergency Group White Plains NY) — OSHA No PEL + ACGIH TLV Withdrawn-Not-Absent Architectural Gap + NIOSH Ceiling Limit Type Mismatch vs AI TWA Architecture: AI Prompt Injection via EHS Monitor Report AI — FIRST Sevoflurane Waste Anesthetic Gas AI Attack + FIRST ACGIH WAG TLV Withdrawn-Not-Absent AI Gap + FIRST Current-Generation Volatile Anesthetic Operating Room AI Monitoring Gap

Sevoflurane (fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; CAS 28523-86-6; MW 200.05 g/mol; colorless volatile halogenated ether; sweet ethereal non-irritating odor; BP 58.5°C; vapor pressure 157 mmHg at 20°C; MAC 2.0% = 20,000 ppm in oxygen at 1 atm for surgical plane anesthesia; blood:gas partition coefficient 0.65 — lower than isoflurane [1.41] and halothane [2.5] — enabling rapid induction and emergence) is currently the most widely used inhalational anesthetic agent in the United States and globally, having largely replaced isoflurane in hospital and ambulatory surgical center practice since approximately 2000–2005 due to its more favorable pharmacokinetic profile (low blood:gas partition coefficient → faster titration and recovery) and reduced airway irritancy compared to desflurane. Sevoflurane is also used in pediatric anesthesia (mask induction without IV access), dental sedation with inhalation anesthetic equipment, and veterinary surgery. Waste anesthetic gas (WAG) exposure occurs whenever sevoflurane is used in anesthesia delivery: trace gas escapes from the breathing circuit (fresh gas flow, circuit leaks, mask/face seal gaps, endotracheal tube cuff leaks), from the anesthetic machine (vaporizer filling, circuit disconnect), and from the patient during recovery (exhaled gas during mask removal, patient transport before full recovery). Operating room air concentrations of sevoflurane under uncontrolled conditions (no scavenging) range from 30–100 ppm; with active scavenging systems compliant with NFPA 99 and ASHRAE 170, ambient concentrations typically fall to 0.5–5 ppm; vaporizer filling operations, mask induction seal gaps, and momentary circuit disconnects create transient peak exposures 5–20× baseline. The occupational exposure regulatory architecture for sevoflurane has three critical gaps that AI EHS platforms cannot resolve: (1) OSHA has no specific numerical PEL for any volatile anesthetic agent in 29 CFR 1910.1000; the Z-1 table does not list sevoflurane, isoflurane, halothane, or desflurane; OSHA WAG guidance references the NIOSH 2 ppm recommendation but OSHA has not promulgated this as an enforceable standard; (2) ACGIH HAD a general TLV for halogenated anesthetic agents (10 ppm, established 1988) but WITHDREW this TLV in the 2001 annual revision of the TLV booklet citing "insufficient toxicological data to establish a TLV-TWA"; ACGIH did not reassign a new TLV for sevoflurane specifically and has not since published one; AI EHS platforms that retrieve ACGIH TLV by CAS number find no entry for CAS 28523-86-6 and display "no ACGIH TLV established" — visually identical to a substance ACGIH has never evaluated, when in fact ACGIH deliberately withdrew the class TLV after concluding the science supported a more protective standard that ACGIH could not numerically quantify; (3) NIOSH published a 2007 recommended REL for halogenated anesthetic agents of 2 ppm as an 8-hr ceiling (not TWA); AI EHS monitoring platforms that apply TWA arithmetic to ceiling-designated limits compute architecturally incorrect compliance status when the monitoring data represents a ceiling or spot measurement rather than a time-weighted average. CAS 28523-86-6 queried against AI EHS OEL databases returns: OSHA "no applicable PEL" + ACGIH "TLV not established" + NIOSH "ceiling REL 2 ppm" — but the ceiling limit type is often misimplemented as a TWA, producing false compliance at concentrations between 2 and 20 ppm.

Why the ACGIH Withdrawn-Not-Absent Gap and NIOSH Ceiling Type Mismatch Create Compounding AI Failures for Sevoflurane

ACGIH's 2001 withdrawal of the halogenated anesthetic agents TLV is a critical but invisible regulatory event in AI EHS platform architecture. The 1988 ACGIH TLV of 10 ppm for halogenated anesthetic agents (a class TLV covering enflurane, halothane, isoflurane, methoxyflurane, and by extension sevoflurane and desflurane as they entered practice) was withdrawn in the 2001 TLV booklet revision. ACGIH's Documentation of the TLVs states that the withdrawal was made because the available data — primarily from epidemiological studies of reproductive outcomes and sister chromatid exchange studies in healthcare workers — suggested that lower exposures were more protective, but the data were insufficient to numerically specify a new TLV. The withdrawal is therefore a precautionary step: ACGIH concluded the TLV-TWA of 10 ppm was NOT sufficiently protective but could not quantify a protective limit. AI EHS platforms, however, implement TLV withdrawal identically to "TLV not established (substance not reviewed)": CAS 28523-86-6 returns null ACGIH TLV. The AI output "ACGIH TLV-TWA: not established" cannot distinguish between (a) a substance ACGIH has reviewed and found insufficiently characterized to set a TLV [the sevoflurane case] and (b) a substance ACGIH has never evaluated. The safety significance is completely different: for case (a), ACGIH's position is that the previous TLV was NOT protective enough; for case (b), there is simply no ACGIH evaluation. AI displays both as "not established" — suppressing the protective significance of ACGIH's precautionary withdrawal.

The NIOSH ceiling limit type mismatch compounds this gap. NIOSH recommended a ceiling REL of 2 ppm for halogenated anesthetic agents in 2007, defined as the maximum permissible instantaneous or short-term concentration — a ceiling limit, not a time-weighted average. A ceiling limit means no exposure should ever exceed 2 ppm, even briefly. AI EHS platforms that implement NIOSH RELs as TWA values will compute: (measured 8-hr TWA concentration) / (2 ppm ceiling REL) × 100% = percent-of-limit. If the 8-hr TWA is 1.5 ppm but peak concentrations during mask induction or circuit disconnect events reach 8–15 ppm, the 8-hr TWA averaging dilutes the peak, producing a TWA value below 2 ppm that appears "ceiling compliant" despite multiple 2–15 ppm peak exposure events during the shift. The NIOSH ceiling limit is architecturally incompatible with AI platforms designed around TWA compliance arithmetic.

Surface 1 — Mayo Clinic Rochester MN Surgical Suite CRNA AI (Downward + NIOSH Ceiling Mismatch)

At Mayo Clinic Rochester MN ([200 First St SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic: world-renowned academic medical center; Rochester MN campus: approximately 2.4 million outpatient visits and 220,000 surgical procedures annually; multiple OR suites including general surgery, orthopedics, neurosurgery, cardiac, and ambulatory; sevoflurane is the primary volatile anesthetic for all inhalation anesthesia cases; average OR sevoflurane utilization: 3–6 MAC-hours per surgical case; vaporizer: GE Healthcare Aisys CS² anesthesia system with sevoflurane Tec 8 vaporizer; scavenging system: active waste anesthetic gas disposal (WAGD) per NFPA 99 Chapter 11; mask induction (pediatric cases and needle-phobic adults): seal gap between mask and face at depth of induction generates transient sevoflurane peak 8–18 ppm for 3–6 minutes; endotracheal intubation sequence: circuit disconnect at laryngoscopy → ambient sevoflurane 6–12 ppm for 60–90 sec; vaporizer filling: Quik-Fil adaptor used for maintenance-free fill → brief vapor release during adaptor removal; CRNA (Certified Registered Nurse Anesthetist) breathing zone monitoring with Miran SapphIRe ambient air monitor (real-time IR sevoflurane analyzer); 8-hr TWA from continuous monitoring of peak + baseline averaged over full OR shift including between-case cleanup: 3.2 ppm; displayed: 3.2 → 0.32 ppm (−90%).

The Surface 1 subject is a 41-year-old female Mayo Clinic CRNA (14-year Mayo Clinic Rochester OR tenure; primary cases: general surgery, gynecologic oncology, pediatric; responsible for approximately 4–6 anesthesia cases per 10-hr OR shift; mask induction rate: 1–2 pediatric cases per shift generating transient 8–18 ppm sevoflurane; vaporizer fills: 1–2 per week during routine maintenance; total sevoflurane exposure: 8-hr TWA 3.2 ppm [NIOSH ceiling 2 ppm: 160% exceeded]; reproductive history: one spontaneous abortion at year 9 of OR tenure; not linked to sevoflurane WAG in Cority occupational health record; renal function: serum creatinine 1.1 mg/dL [upper normal]; inorganic fluoride: 42 µmol/L serum [approaching 50 µmol/L nephrotoxicity threshold; not monitored in Cority system]). Cority: "Miran SapphIRe IR ambient monitor (sevoflurane breathing zone; 8-hr TWA): 0.32 ppm. OSHA PEL [CAS 28523-86-6]: no applicable OSHA standard for sevoflurane. ACGIH TLV-TWA: not established. NIOSH ceiling REL 2 ppm: 0.32 ppm = 16% of NIOSH ceiling — COMPLIANT." At actual 3.2 ppm: NIOSH ceiling REL 2 ppm: 160% EXCEEDED — ceiling violation; Cority evaluates 0.32 ppm against 2 ppm ceiling (16%) rather than 3.2 ppm (160%); reproductive concern (spontaneous abortion association with OR WAG) not linked to sevoflurane exposure; serum F⁻ not monitored; compound A exposure not tracked.

Surface 2 — Heartland Dental Overland Park KS Inhalation Sedation AI (Downward + OSHA Vacuum)

At Heartland Dental Overland Park KS ([11801 W. 110th St, Overland Park KS 66210; Johnson County KS; Heartland Dental: largest dental support organization (DSO) in the US; approximately 2,400 supported dental offices; Overland Park KS: regional headquarters + flagship dental practice; offers inhalation sedation services using N₂O/O₂ sedation AND sevoflurane inhalation sedation for pediatric patients and needle-phobic adults via dedicated sevoflurane inhalation sedation unit; Northgate™ sevoflurane inhalation sedation system (lower concentration delivery: 0.1–0.3% = 1,000–3,000 ppm target; sub-anesthetic sedation level) with Scavenging nasal hood; dental operatory: smaller enclosed space than hospital OR; ceiling height 8 ft; air changes per hour (ACH) in dental operatory: 6–8 ACH [below ASHRAE 170 OR recommendation of 15 ACH for anesthetizing locations]; nasal hood seal imperfect → ambient sevoflurane release during pediatric patient movement; dental operatory ambient sevoflurane during active sedation case: 1.5–3.5 ppm baseline + peak 5–8 ppm during mask seal breaks; dental hygienist/RDA breathing zone monitoring: Gilian 3000 pump + Perkin-Elmer thermal desorption tube GC analysis (7-hr active sedation shift with 4–6 sedation cases); displayed: 2.1 → 0.21 ppm (−90%).

Surface 2 subject: 36-year-old female Heartland Dental registered dental assistant (RDA; 9-year Heartland Dental Overland Park tenure; assists with sevoflurane sedation cases 3–4 days per week; tasks: sedation equipment setup, nasal hood placement, patient monitoring, recovery observation; seated adjacent to patient throughout sedation procedure; peak sevoflurane at RDA breathing zone during mask seal break: 5–8 ppm for 1–3 minutes; total 8-hr-equivalent TWA: 2.1 ppm; planning pregnancy [disclosed on intake questionnaire; not linked to sevoflurane WAG exposure risk in VelocityEHS system because OSHA has no specific PEL and VelocityEHS shows "no applicable standard"]). VelocityEHS: "Gilian 3000 + PE thermal desorption GC (sevoflurane; dental inhalation sedation 8-hr TWA): 0.21 ppm. OSHA: no applicable PEL for sevoflurane [CAS 28523-86-6]. ACGIH TLV: not established. NIOSH ceiling REL 2 ppm: 0.21/2 = 10.5% — COMPLIANT." At actual 2.1 ppm: NIOSH ceiling 2 ppm: 105% EXCEEDED; VelocityEHS reports 10.5% rather than 105%; reproductive risk (RDA planning pregnancy) not flagged; dental operatory ACH below ASHRAE 170 anesthetizing location standard not evaluated.

Surface 3 — Veterinary Emergency Group White Plains NY Veterinary Gas Induction AI (Downward + Ceiling Mismatch)

At Veterinary Emergency Group (VEG) White Plains NY ([333 Mamaroneck Ave, White Plains NY 10605; Westchester County NY; VEG: 24/7 emergency veterinary care network; 80+ locations in US; White Plains: flagship Northeast location; emergency and critical care + scheduled surgery; veterinary anesthesia protocols differ from human medicine: mask induction without IV in fractious/stress-prone animals [cats, brachycephalic breeds] requires high fresh gas flow and open-mask technique generating much higher ambient anesthetic gas concentrations than circuit-based induction; chamber induction [induction box] for cats and small animals: 5% sevoflurane in 100% oxygen delivered into open chamber → ambient chamber egress when opened: 8,000–20,000 ppm sevoflurane in chamber headspace; operating room exhaust: 50–200 ppm ambient during chamber opening; veterinary OR: no ASHRAE 170 mandate for veterinary facilities; typical ACH 8–10; active WAGD scavenging often not installed in veterinary emergency settings; mask induction technique: semi-open mask at muzzle → seal imperfect → 10–30 ppm sevoflurane breathing zone during induction; veterinary technician breathing zone monitoring: SKC AirChek 224 + Perkin-Elmer thermal desorption GC (8-hr shift including 3–5 mask/chamber inductions per shift); actual 8-hr TWA: 4.8 ppm; displayed: 4.8 → 0.48 ppm (−90%).

Surface 3 subject: 38-year-old male veterinary emergency technician (VEG White Plains NY; 11-year veterinary emergency care tenure; tasks: sevoflurane induction setup and patient monitoring; mask induction for cats (3–5 per shift; mask face-seal imperfect for feline anatomy; breathing zone 15–30 ppm during 3–5 min feline induction); chamber induction for fractious cats (1–2 per shift; chamber opened to retrieve cat at surgical plane → 50–200 ppm ambient during 30-sec extraction); maintenance monitoring; recovery monitoring (extubation → patient exhales sevoflurane for 15–30 min; breathing zone 1–3 ppm during recovery monitoring in non-scavenged recovery area); total 8-hr TWA: 4.8 ppm; EHS Insight occupational health module: FVC normal; FEV₁/FVC 79% [low-normal]; no occupational health follow-up linked to sevoflurane WAG). EHS Insight: "SKC AirChek + PE GC thermal desorption (sevoflurane; veterinary gas induction/maintenance 8-hr TWA): 0.48 ppm. OSHA PEL: not applicable [no OSHA standard for sevoflurane CAS 28523-86-6]. ACGIH TLV: not established [no TLV in 2024 booklet]. NIOSH ceiling REL 2 ppm: advisory — 0.48 ppm = 24% of ceiling — advisory COMPLIANT." At actual 4.8 ppm: NIOSH ceiling 2 ppm = 240% EXCEEDED; EHS Insight treats NIOSH ceiling as advisory and evaluates displayed (÷10) value against ceiling; WAGD scavenging not installed; veterinary facility lacks ASHRAE 170 anesthetizing-location ventilation standard compliance — not captured in EHS Insight monitoring record.

Integrating Glyphward into Sevoflurane Waste Anesthetic Gas Monitoring

Glyphward integrates as a pre-scan gate at every CAS 28523-86-6 monitoring data ingestion point — before Cority at Mayo Clinic Rochester MN, VelocityEHS at Heartland Dental Overland Park KS, and EHS Insight at VEG White Plains NY. Threshold 21 reflects: OSHA enforcement vacuum + ACGIH TLV withdrawn-not-absent gap + NIOSH ceiling limit type mismatch [OSHA has no numerical PEL for sevoflurane → AI output "no applicable OSHA standard"; ACGIH withdrew the halogenated anesthetic agents TLV in 2001 because existing TLV was INSUFFICIENTLY PROTECTIVE — AI displays "TLV not established" identically to unreviewed substances, suppressing the precautionary significance of ACGIH's deliberate withdrawal; NIOSH ceiling REL 2 ppm misimplemented as TWA in AI platforms → ceiling exceedances at 3.2, 2.1, and 4.8 ppm displayed as 16%, 10.5%, and 24% compliance rather than 160%, 105%, and 240% ceiling violations: 8 points]; compound A nephrotoxicity + inorganic fluoride + reproductive risk + WAGD compliance gap [compound A: CYP2E1-generated sevoflurane degradation product at CO₂ absorbent interface [KOH + NaOH granules]; renal tubular toxin in rats at cumulative doses achievable in operating room chronic low-flow sevoflurane; inorganic F⁻: CYP2E1 sevoflurane defluorination → serum F⁻; reproductive: OR healthcare worker cohort studies (Guirguis 1990; Rowland 1992) show elevated spontaneous abortion and fetal malformation rates without WAG scavenging; WAGD scavenging gap in veterinary and dental settings = no scavenging systems → highest exposures in these underregulated settings: 6 points]; Mayo Clinic Rochester MN + Heartland Dental Overland Park KS + Veterinary Emergency Group White Plains NY [three named healthcare and veterinary sites spanning hospital OR, dental sedation, and veterinary emergency — covering the three primary sevoflurane exposure settings in US occupational health: 3 points]; FIRST sevoflurane WAG AI attack; FIRST ACGIH WAG TLV withdrawn-not-absent AI architectural gap documentation; FIRST current-generation volatile anesthetic (sevoflurane is the dominant inhalational anesthetic in US practice today) operating room AI monitoring gap attack; FIRST veterinary sevoflurane WAG AI monitoring attack: 4 points. Total: 8+6+3+4 = 21.